The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Determining The Clinical Relevance Of Intratumour Heterogeneity In Breast Cancer And Its Relationship To Metastases Formation
Funder
National Health and Medical Research Council
Funding Amount
$314,644.00
Summary
Breast cancer metastasis is generally an incurable disease, yet it is not well-understood. This project aims to understand how cancer metastasises by using a novel and unique approach of analysing multiple regions from matched primary and metastatic tumours from breast cancer patients. Expected outcomes include identifying predictors of treatment resistance and resultant personalised management and therapeutic strategies to improve survival outcomes of breast cancer patients.
Neuroblastoma (NB) is a common cancer in children, and one of the hardest to cure. Some mature into a benign tumour without needing any treatment, others are aggressive and require intensive treatment, and some regrow despite all treatment. It is often difficult to predict accurately how NBs will behave. We will study the two ways NBs can undergo unlimited growth, to determine whether this predicts tumour behavior, and therefore what treatment is needed.
Novel Therapeutic Strategies For Pancreatic Cancer Using Next Generation Sequencing
Funder
National Health and Medical Research Council
Funding Amount
$354,892.00
Summary
Dr David Chang is a surgeon scientist who specialises in the treatment of pancreatic cancer. His research focus is on the development and implementation of novel therapeutic strategies for pancreatic cancer. He aims to achieve this by utilising novel biomarkers that have the ability to forecast prognosis and response to treatments. Ultimately, this will lead to the “individualised” treatment for each patient.
Investigating The Cellular Requirement For STIM1 Phosphorylation And Store-operated Calcium Entry Suppression During Mitosis: Roles In Development And Cancer
Funder
National Health and Medical Research Council
Funding Amount
$344,900.00
Summary
Cells are constantly interacting with and modifying their surrounding environment. The intracellular calcium signal is one mechanism cells use to translate signals from the microenvironment into cellular responses. This proposal seeks to explore why a key calcium signalling pathway, known as store-operated calcium entry, is specifically silenced during cell division, and to determine how reversing this inhibition affects cell division during normal development and in cancer.
Therapeutic Targeting Of The Hedgehog Signaling Pathway In Premalignant Lesions Of The Breast.
Funder
National Health and Medical Research Council
Funding Amount
$115,980.00
Summary
Breast screening has been successful in reducing deaths from breast cancer. Unfortunately it also detects increasing numbers of precancerous changes. Treatment of these changes is often aggressive, using surgery and radiotherapy. However we are unable to predict exactly which of the changes we need to treat. We aim to better understand the changes involved in this progression and try to block them using new drugs.
This project will investigate a new class of targeted drugs called Smac-mimetics. These drugs are proving extremely effective in promoting the death of cancer cells. Here, we aim to better understand how Smac-mimetics work as a cancer therapeutic and how they promote immune responses to cancer. This will enable us to identify combination therapies that elicit both death of the cancer cell and stimulate the immune system to promote tumour clearance.